Hyperfine
147 E 82nd Street #2F
New York, NY 10028

Bridget Osetinsky, CEO
T 425-343-9282
Email: bridget.osetinsky@hyperfineglobal.com
www.hyperfineglobal.com

Hyperfine

Industry:
_____Pharma
___X__Biotech
_____Medical Device
_____Diagnostic
_____Other (declare)

Management:
- Executive Leadership:

Bridget Osetinsky, CEO
Bobby Mannepalli, COO
Dr Abdul Aziz, CTO

- Board:

Aaron Galaznik, MD, MBA
Pfizer's Senior Director of Real World
Data and Analytics

Number of Employees: 3

Finance:
- Financing to Date: Self funded

- Amount of Financing Sought: $3M for series A To accomplish our first year of development, and have V1 of the product sold to 3 customers. Funds will go to developers, servers, and IP.

Legal:
- IP: Shirley Fung with Patent Capital Group

Please indicate primary purpose of Presentation:

Executive Summary: Hyperfine is developing analytics which will advance our understanding of diseases & accelerate drug discovery by providing medical researchers with entirely new methods for arriving at new hypotheses & understanding complex causal relationships.

Company History: The company was founded in 2010.
2010: First method MLA developed & patent filed
2011: CTO Joined
2012: Second method CNM on language developed & patent filed
2013: COO Joined
     Pfizer pilot of first method
2014: Second method CNM on networks developed & patent filed
     Mount Sinai School of Medicine pilot of second method.

Market Opportunity / Unmet Need: Precision medicine has two dominant roadblocks in analytics today. 1) Complex diseases are caused by many interdependent risk factors, not single causal relationships. With current software researchers are not able to study complex disease causation. 2) Predictive models of disease today are developed by identifying the connections between elements but no software studies the underlying reasons for the connections, thus stunting the models. There are 1000 teaching hospitals in the US that are candidates for this software to aid in their clinical decisions & research. Affecting their cost savings in targeted patient care & increasing the pace & effectiveness of research on complex diseases.

Products/Services – Launched & Pipeline:
Our product is advanced analytics software comprised of two methods. The first method provides the framework for the researcher to study interdependent variables of complex causation. The second method helps uncover underlying reasons for the connections within a network using the reasons to build more detailed/active/fundamental predictive models of disease to better prevent, diagnose & treat the patient.

Commercial / Technical Milestones: The three technical milestones are version 1: both methods working on big data (complete by the end of year 1). Version 2: both methods working on big data changing in real time. Version 3: both methods working on unmonitored/less reliable big data like patient chat forums, changing in real time. Version 2 & 3 will be completed in the second year of development & piloted in collaboration with several additional leading research institutions that will publish papers with us, establishing our credibility. With that reputation we will sell the 3rd version of our product to 12 customers.

Intellectual Property: 3 pending patents.
Patent 1: US (in office action) & EU pending
Patent 2: US pending & EU (in office action)
Patent 3: Provisional converting to US & EU in August

Competition: Ayasdi, Berg, Palantir, Numedii, IBM Watson
None of our competitors' technologies solve the two critical pain points of analyzing complex causation & analyzing the underlying forces.

Financial Projections (Unaudited): At the end of year one we would have a first version of the product & we are expecting to have 3 customers making

$900,000. In year 2 & 3 we are expecting to have 12 & 39 customers respectively, generating $3.9M & $13.4M. Year 4 120 customers & $42.9M in revenue. By year 4 reaching profitability.